NASDAQ:FATEFate Therapeutics Stock Price, Forecast & News

Fate Therapeutics' stock was trading at $23.79 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, FATE shares have increased by 18.6% and is now trading at $28.21. View which stocks have been most impacted by Coronavirus.

17 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Fate Therapeutics in the last year. There are currently 2 hold ratings and 15 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Fate Therapeutics.

Fate Therapeutics is scheduled to release its next quarterly earnings announcement on Tuesday, August 4th 2020. View our earnings forecast for Fate Therapeutics.

Fate Therapeutics Inc (NASDAQ:FATE) issued its earnings results on Monday, May, 11th. The biopharmaceutical company reported ($0.44) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.39) by $0.05. The biopharmaceutical company had revenue of $2.52 million for the quarter, compared to the consensus estimate of $1.69 million. Fate Therapeutics had a negative net margin of 1,059.44% and a negative return on equity of 52.08%. The company's quarterly revenue was down 4.4% on a year-over-year basis. During the same quarter in the previous year, the company posted ($0.30) earnings per share. View Fate Therapeutics' earnings history.

17 equities research analysts have issued 12 month price targets for Fate Therapeutics' stock. Their forecasts range from $25.00 to $57.00. On average, they expect Fate Therapeutics' share price to reach $35.88 in the next twelve months. This suggests a possible upside of 27.2% from the stock's current price. View analysts' price targets for Fate Therapeutics.

Press coverage about FATE stock has been trending neutral on Saturday, InfoTrie Sentiment reports. InfoTrie identifies positive and negative press coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Fate Therapeutics earned a news sentiment score of 0.4 on InfoTrie's scale. They also assigned media coverage about the biopharmaceutical company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an effect on the stock's share price in the near term. View the latest news aboutFate Therapeutics.

Some companies that are related to Fate Therapeutics include Repligen (RGEN), Allogene Therapeutics (ALLO), Adaptive Biotechnologies (ADPT), Acceleron Pharma (XLRN), Spark Therapeutics (ONCE), China Biologic Products (CBPO), Iovance Biotherapeutics (IOVA), Crispr Therapeutics (CRSP), Ablynx (ABLYF), bluebird bio (BLUE), Momenta Pharmaceuticals (MNTA), Halozyme Therapeutics (HALO), Denali Therapeutics (DNLI), Novavax (NVAX) and Alector (ALEC). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Fate Therapeutics investors own include Cara Therapeutics (CARA), Crispr Therapeutics (CRSP), Sangamo Therapeutics (SGMO), Juno Therapeutics (JUNO), Sorrento Therapeutics (SRNE), Amarin (AMRN), Exelixis (EXEL), Gilead Sciences (GILD), TG Therapeutics (TGTX) and Clovis Oncology (CLVS).

Fate Therapeutics trades on the NASDAQ under the ticker symbol "FATE."

Fate Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (7.36%), Victory Capital Management Inc. (4.58%), Victory Capital Management Inc. (4.58%), Janus Henderson Group PLC (4.34%), State Street Corp (3.25%) and Franklin Resources Inc. (1.51%). Company insiders that own Fate Therapeutics stock include Amir Nashat, Bahram Valamehr, Cindy Tahl, Daniel D Shoemaker, J Scott Wolchko and Redmile Group, Llc. View institutional ownership trends for Fate Therapeutics.

FATE stock was sold by a variety of institutional investors in the last quarter, including Victory Capital Management Inc., Victory Capital Management Inc., Pictet Asset Management Ltd., Franklin Resources Inc., Sofinnova Investments Inc., Morgan Stanley, Morgan Stanley, and BlackRock Inc.. Company insiders that have sold Fate Therapeutics company stock in the last year include Amir Nashat, Bahram Valamehr, Cindy Tahl, Daniel D Shoemaker, and J Scott Wolchko. View insider buying and selling activity for Fate Therapeutics.

FATE stock was acquired by a variety of institutional investors in the last quarter, including Janus Henderson Group PLC, Federated Hermes Inc., Invesco Ltd., Asymmetry Capital Management L.P., Nikko Asset Management Americas Inc., Nikko Asset Management Americas Inc., Sumitomo Mitsui Trust Holdings Inc., and State Street Corp. View insider buying and selling activity for Fate Therapeutics.

Shares of FATE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of FATE stock can currently be purchased for approximately $28.21.

Fate Therapeutics has a market capitalization of $2.19 billion and generates $10.68 million in revenue each year. The biopharmaceutical company earns $-98,150,000.00 in net income (profit) each year or ($1.44) on an earnings per share basis. Fate Therapeutics employs 104 workers across the globe.

The official website for Fate Therapeutics is www.fatetherapeutics.com.

Fate Therapeutics' mailing address is 3535 GENERAL ATOMICS COURT SUITE 200, SAN DIEGO CA, 92121. The biopharmaceutical company can be reached via phone at 858-875-1800 or via email at [email protected]